What's Next for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals is developing sotagliflozin, branded as Zynquista, to help treat symptoms of both type 1 and type 2 diabetes. The drug targets two proteins that affect how well the kidneys and intestines eliminate glucose from the body. If successful, then it could be another tool helping patients manage their blood glucose levels in addition to insulin therapy.